Cresaryn

MENU

Partner with us

A differentiated erectile-dysfunction asset built around an established molecule

For investors and strategic partners

Patented Delivery Platforms

For investors and strategic partners, Cresaryn offers a differentiated erectile-dysfunction asset built around an established molecule, a patented delivery platform and a defined path to human proof. The opportunity is not simply a spray. It is the potential foundation of a broader franchise that an established pharmaceutical owner can accelerate using capabilities it already possesses.

Add value through regulatory, clinical, CMC, device and manufacturing infrastructure.

Shorten the route to broad patient availability

A partner can add value immediately through regulatory, clinical, CMC, device and manufacturing infrastructure. Existing prescriber relationships, telehealth partnerships, pharmacy access and international commercial channels can shorten the route from clinical validation to broad patient availability.

A strategic owner may also be able to pursue parallel priority-market filings rather than sequencing expansion country by country.

Creating lifecycle potential across alternative doses

The lead tadalafil program targets a proposition built around discretion, convenient metered delivery, earlier-exposure potential and tadalafil’s established duration. Human studies are still required to validate the target profile. Near-term local-safety, pilot pharmacokinetic and IND milestones provide clear opportunities to retire risk and reassess value.

The licensed field creates lifecycle potential across alternative doses, additional territories and other generic erectile-dysfunction active ingredients. Cresaryn is funded through its key near-term development activities, allowing partnering discussions to focus on strategic fit and long-term value. Specific buyer assessments and rankings remain confidential.

Submit an opportunity

We welcome confidential enquiries from pharmaceutical companies, licensing teams, investors, development partners and advisers with a relevant proposal for Cresaryn.

Please provide your name, role, organisation, contact details, proposal type, relevant therapeutic or commercial experience and a short description of the opportunity.

Do not submit patient information, medical enquiries or highly confidential technical material through this form. Our team will review the submission and contact appropriate parties directly. Detailed product, diligence or transaction information may be shared only after identity checks and, where appropriate, execution of a mutual confidentiality agreement. Submission of an enquiry does not create an obligation, agency relationship or commitment to enter a transaction.